Odyssey Health acquires option to purchase PRV-001 patents from Prevacus for 1M shares

Odyssey Health, Inc.

Option to buy 100% of worldwide patents to PRV-001 and an Enantiomer from Prevacus.
Consideration for option: 1,000,000 shares of Odyssey common stock.
If exercised, asset purchase price: 2M shares for PRV-001, 1M shares for Enantiomer.
Option exercisable within 180 days of Nov 22, 2022; closing within 90 days after exercise.
Odyssey will also enter an asset purchase agreement upon exercise.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Odyssey Health, Inc. entered into Option to Purchase Intellectual Property Agreement with Prevacus, Inc. (effective 2022-11-21).

Action: entry
Agreement: asset purchase
Counterparty: Prevacus, Inc.
Effective: 2022-11-21

Exact text from the filing

On November 21, 2022, Odyssey Health, Inc. (the “Company” “Odyssey”) entered into an Option to Purchase Intellectual Property Agreement (the “Option Agreement”) with Prevacus, Inc. (“Prevacus”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Odyssey Health, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-008027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.